Illumina 16. Feb. 2026 Decoding early synaptic failure in Alzheimer’s disease through multiomic analysis - Illumina
Illumina 16. Feb. 2026 Illumina’s AI-Driven Data Vision Is Expanding — Will Multiomics Integration Unlock a Transformational Edge? - Smartkarma
Illumina 16. Feb. 2026 Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating - TipRanks
Illumina 16. Feb. 2026 The future of global food security may depend on quality agrigenomics software - Illumina
Illumina 15. Feb. 2026 Illumina Conservation Deal Highlights New Genomics Demand And Valuation Debate - simplywall.st
Illumina 14. Feb. 2026 Illumina (NASDAQ:ILMN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Illumina 13. Feb. 2026 From sample to insight: Streamlining analysis with the Illumina 5-base solution - Illumina
Illumina 13. Feb. 2026 Illumina, Inc. $ILMN Stock Holdings Lowered by Rhumbline Advisers - MarketBeat
Illumina 12. Feb. 2026 Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips - Zacks Investment Research
Illumina 12. Feb. 2026 Why Illumina (ILMN) Is Down 12.9% After 2026 Outlook And SomaLogic Deal Close - And What's Next - simplywall.st
Illumina 12. Feb. 2026 Illumina Director Makes Bold Insider Move With Fresh Stock Purchase - TipRanks
Illumina 11. Feb. 2026 Whole-genome sequencing in the UK and Europe, with Mark Robinson - pharmaphorum
Illumina 11. Feb. 2026 Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com